A&G PHARMACEUTICAL, INC.
Anti-GP88 monoclonal antibody (AG1) therapeutic with companion diagnostic tests for triple-negative and hormone-resistant breast cancer
- Sector
- Biotech
- Headquarters
- Columbia, MD
- Latest Form D
- $100K, Apr 2010
- Total capital
- $9.2M
- Federal grants
- $4.9M
- 3 awards · 2017–2020
- Rank in peer group#174 of 514
- Private capital raised
- $100K
- 1 Form D · last Apr 2010
- 198 months since last filing
- Federal contracts
- $4.2M
- 63 awards · Health and Human S, Veterans Affairs, Defense
- Rank in Biotech#92 of 4373
- Granted patents
- 2
- 26 pending · first 2023
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Federal contractHealth and Human S · To Generate Reagents Against AZM-152, A Drug Candidate From Tdb Azome Project.$14K
- Federal contractHealth and Human S · Monoclonal Antibody Against MARCH1 Preparation MAB-P3-00-001, 002, 003, 005 And MAB-P3-HC-001 (ambis #2254762)$17K
- Federal contractHealth and Human S · Precision Antibody (ambis #2229539) Lab Testing, Fusion, Cloning$16K
- Federal contractHealth and Human S · Task Order 7 - DOK7$106K
- Federal contractHealth and Human S · TO6 - Generating Monoclonal Cell Lines, Monoclonal Antibodies, And Labeled Monoclonal Antibodies Against Human And Mouse Colq$133K
- Federal contractHealth and Human S · Custom Monoclonal Antibodies$15K
- Federal contractHealth and Human S · Polyclonal Rat Antibody And Monoclonal Rat Antibodies Against Glycol-chitosan Nanoparticles$83K
- Private capital raisedForm D · SEC · 1st filing$100K
Show 51 earlier federal awards
- Federal contractHealth and Human S · Generating Monoclonal Cell Lines, Monoclonal Antibodies, And Labeled Monoclonal Antibodies Against Pth-ia, Pop 5/26/21 - 5/25/2022.$41K
- Federal contractHealth and Human S · Generating Polyclonal Antibodies Against Pth-ia, Period Of Performance 9/29/20 - 9/28/2021$27K
- Federal grantHealth and Human S · Phase II · Pharmacology and human Phase 1 safety and dose escalation studies using anti-GP88 in aggressive breast cancer$1.9M
- Federal contractHealth and Human S · Nih-approved Covid-related Project: Analysis Of A Novel Truncated Form Of ACE2 Receptor$19K
- Federal contractDefense · Antibody Development-phase 11 Electrofusion, Antibody, Development -phase 11 Supernantant Shipment, Antibody Development-phase 1V: Cell Culture&supernatant Preparation, Antibody Development- Phase V: Delivery Of 3 Vials/ Clone Up To 5 Clones$19K
- Federal contractHealth and Human S · Generating Drug Specific Monoclonal Antibodies Against TTHX1114, An Engineered Mutant Human FGF1$50K
- Federal contractAgriculture · PEPT001 Antibody Development - Peptide Synthesis Per Amino Acid. Peptide #1 And #2 Sequence.$12K
- Federal contractHealth and Human S · A&g Pharmaceutical INC:1108556 [19-012522]$23K
- Federal contractHealth and Human S · A&g Pharmaceutical INC:1108556 [19-012467]MONOCLONAL Antibody (mab) Development$15K
- Federal contractHealth and Human S · A&g Pharmaceutical INC:1108556 [19-006920]$8K
- Federal contractHealth and Human S · Monoclonal Antibody Productionquantity Of 9@ $1,543.75 Each$14K
- Federal contractHealth and Human S · Biological$5K
- Federal grantHealth and Human S · Phase II · Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies$2M
- Federal contractHealth and Human S · Antibodies (clones, Electrofusion,immunizations)$13K
- Federal contractHealth and Human S · Monoclonal Antibody Generation$16K
- Federal contractHealth and Human S · Igf::ot::igf Smart Fusion: High Affinity Peptide Capture Reagents$1.0M
- Federal contractHealth and Human S · Monoclonal Antibody Immunizations/productions In Mice$20K
- Federal contractHealth and Human S · Igf::ot::igf Influenza Antibody Production$17K
- Federal contractHealth and Human S · Mouse Monoclonal Antibody Development (see Quote For Project Details)$11K
- Federal contractHealth and Human S · Igf::ot::igf Title: Development Of Novel Anticancer Agent To Potentiate Sensitivity To Anti-estrogen Therapy$1.5M
- Federal contractAgriculture · Igf::ot::igf Monoclonal Antibody (moab) Development Service$24K
- Federal contractHealth and Human S · Igf::ot::igf Monoclonal Antibody (moab) Development Service$22K
- Federal contractHealth and Human S · Igf::ot::igf, For Other Functions, Custom Antibody Generations.$5K
- Federal contractHealth and Human S · Precision Antibody Quote # 4862 Antibody Production - 1MG$30K
- Federal contractHealth and Human S · Igf::ot::igf For Other Functions A&g Pharmaceutical Inc Monoclonal Antibody Production$6K
- Federal contractHealth and Human S · Igf::ot::igf Technology Generated Anti-peptide Capture Reagents For Affinity Enriched Proteomic Studies$200K
- Federal contractHealth and Human S · Precision Antibody Monoclonal Antibodiesquote # 4608$10K
- Federal contractHealth and Human S · Monoclonal Antibody Production$11K
- Federal contractHealth and Human S · Precision Antibody Quote # 4026RCUSTOM Antibodies$14K
- Federal contractHealth and Human S · Igf::ot::igf For Other Functions$8K
- Federal contractHealth and Human S · Igf::ot::igf R&d Medical: Biomedical$199K
- Federal contractHealth and Human S · Antigen Production$38K
- Federal contractHealth and Human S · Precision Antibody - AMBIS#1550126$8K
- Federal contractDefense · 1 Gram Purified Antibody Production With Documentation Package For Scientific Research$17K
- Federal contractHealth and Human S · Drugs And Biologicals$329K
- Federal contractHealth and Human S · TAS::75 0600::TAS Monoclonal Antibodies$10K
- Federal contractHealth and Human S · Precision Antibody (ambis #1530429)$3K
- Federal contractHealth and Human S · TAS::75 0894::TAS A& G Pharmaceutical (precision Antibody) [11-000810]$6K
- Federal contractHealth and Human S · TAS::75 0844::TAS$16K
- Federal contractHealth and Human S · TAS::75 0943::TAS Monoclonal Antibody$5K
- Federal contractHealth and Human S · TAS::75 0600::TAS Precision Antibody (NIH Bpa Mab Phase I Immunization - Item G-MAB001PHI) End-user Dr Pei Zhang (cber Obrr Dh)$8K
- Federal contractHealth and Human S · TAS::75 0885::TAS Ab Fusion$5K
- Federal contractEnvironmental Prot · Service Contact For Generation Of C. Parvum And C. Hominis Specific Monoclonal Antibodies$15K
- Federal contractHealth and Human S · LAW927784 Antibody/production Cloning & Screening CAT#MAB002$5K
- Federal contractDefense · Mab Cloning And Screening$10K
- Federal contractHealth and Human S · Clones From Project NIA047CAT#MAB010$3K
- Federal contractHealth and Human S · Purified Monoclonal Antibody 1 MGCAT#MAB016$4K
- Federal contractHealth and Human S · Mouse Monocolonal Antibody$9K
- Federal contractVeterans Affairs · Cloning And Screening$10K
- Federal contractHealth and Human S · LAW815006 Immunization, Tb, Fusion, Start Up CAT#MAB001 Lab Test Services$9K
- Federal contractHealth and Human S · 00HCVHDC-2007-46243 - A&g Pharmaceutical Inc$3K
Federal awards are summed by year (58 awards); hover a bar for the split. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
8 records have no date or no amount, so they aren’t placed on the timeline.
Federal first
32months
from A&G PHARMACEUTICAL, INC.’s first federal award to its first private round.
- First federal award · Sep 2007
- Health and Human S · $3K
- First Form D · Apr 2010
- $100K · 1st Form D
- Awards before first raise
- 8 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#174 · top 34%
- Granted patents#142 · top 28%
- Linked publications#6 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Ginette SerreroResearcherExecutive Officer, DirectorLinked by 1 patent · $3.9M in grants as PI
- Jun HayashiResearcherExecutive OfficerLinked by 1 patent · $1M in grants as PI
- Gordon SatoDirectorNamed in SEC Form D filings
- Jennie MatherDirectorNamed in SEC Form D filings
- Lars HananDirectorNamed in SEC Form D filings
- Michael KeefeExecutive OfficerNamed in SEC Form D filings
Show all 8 people
- Seung-Suh HongDirectorNamed in SEC Form D filings
- Tom HancockDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 28- PendingFully Human Monoclonal Antibodies Against Human HER-2USPTOApplication 19120405
- PendingFully Human Monoclonal Antibodies Against Human HER-2 And Methods For Using The SameUSPTOApplication 19306837
- PendingFully Human Monoclonal Antibodies Against Human ProgranulinUSPTOApplication 18838875
Show all 28 patent records
- Fully Human Monoclonal Antibodies Against Human HER-2May 14, 2026 · Application 19120405Pending
- Fully Human Monoclonal Antibodies Against Human HER-2 And Methods For Using The SameMay 7, 2026 · Application 19306837Pending
- Fully Human Monoclonal Antibodies Against Human ProgranulinMay 15, 2025 · Application 18838875Pending
- Monoclonal Antibodies And Conjugates Against Prostaglandin F2 Receptor Inhibitor And Uses ThereofJun 20, 2024 · Application 18078378Pending
- Materials And Methods For The Development Of An Antigen-specific Immune Non-responsiveness StateOct 31, 2023 · US 11,801,287Granted
- Monoclonal Antibodies And Conjugates Against Prostaglandin F2 Receptor Inhibitor And Uses ThereofJan 17, 2023 · US 11,555,074Granted
- Materials And Methods For The Development Of An Antigen-specific Immune Non-responsiveness StateJan 2, 2020 · Application 16558600Pending
- Materials And Methods For The Development Of An Antigen-specific Immune Non-responsiveness StateDec 8, 2016 · Application 15231234Pending
- Methods For Diagnosing Cancer And Determining The Overall Survival And Disease-free Survival Of Cancer PatientsSep 22, 2016 · Application 15089770Pending
- Methods For Diagnosing Cancer And Determining The Overall Survival And Disease-free Survival Of Cancer PatientsApplication 14831308Pending
- Methods For Diagnosing Cancer And Determining The Overall Survival And Disease-free Survival Of Cancer PatientsApplication 14590527Pending
- Methods For Diagnosing Cancer And Determining The Overall Survival And Disease-free Survival Of Cancer PatientsApplication 14521859Pending
- Materials And Methods For The Development Of An Antigen-specific Immune Non-responsiveness StateApplication PCTUS2010045753Pending
- Methods For Diagnosing Cancer And Determining The Overall Survival And Disease-free Survival Of Cancer PatientsApplication PCTUS2009056240Pending
- Autocrine Growth Factor Receptors And MethodsApplication PCTUS2005036876Pending
- Compositions And Methods For Restoring Sensitivity To Treatment With HER2 AntagonistsApplication PCTUS2004024593Pending
- Compositions And Methods For Restoring Sensitivity Of Tumor Cells To Antitumor Therapy And Inducing ApoptosisApplication PCTUS2004020036Pending
- Antibodies And Conjugates Against Prostaglandin F2 Receptor Inhibitor And Uses ThereofApplication 19474493Pending
- Cancer Specific Monoclonal AntibodiesApplication PCTUS2004012568Pending
- Methods And Kits For Diagnosing TumorigenicityApplication PCTUS2003034146Pending
- Fully Human Monoclonal Antibodies Against Human HER-2 And Methods For Using The SameApplication 63685564Pending
- Antibodies And Conjugates Against Prostaglandin F2 Receptor Inhibitor And Uses ThereofApplication PCTUS2024023629Pending
- Fully Human Monoclonal Antibodies Against Human HER-2Application PCTUS2023076877Pending
- Antibodies And Conjugates Against Prostaglandin F2 Receptor Inhibitor And Uses TherofApplication 63495835Pending
- Fully Human Monoclonal Antibodies Against Human ProgranulinApplication PCTUS2023063169Pending
- Fully Human Monoclonal Antibodies Against Human HER-2Application 63416270Pending
- Fully Human Monoclonal Antibodies Against Human ProgranulinApplication 63313304Pending
- Monoclonal Antibodies And Conjugates Against Prostaglandin F2 Receptor Inhibitor And Uses ThereofApplication PCTUS2018055905Pending
Recent research by its founders
- Comprehensive angiographic evaluation of graft quality after endoscopic vein harvesting in coronary artery bypass grafting20261 cites
- Abstract 3168: Fully human anti-HER-2 antibodies to HER-2 domains distinct from trastuzumab as antibody drug conjugates for tumor growth inhibition20260 cites
- Abstract 5646: Fully human monoclonal antibodies for antibody drug conjugate development to a cell surface target expressed in cancers with unmet needs.20260 cites
Related companies, and why
- Unchained LabsSimilar federal contract value in Biotech · $4.4M in contracts
- NANOCELLECT BIOMEDICAL INCSimilar federal contract value in Biotech · $4.3M in contracts
- BIOINFOEXPERTS LLCSimilar federal contract value in Biotech · $4.3M in contracts
- UNIVERSAL STABILIZATION TECHNOLOGIES, INC.Similar federal contract value in Biotech · $4.2M in contracts
- Tissue Genesis, IncSimilar federal contract value in Biotech · $4.2M in contracts
- ALAMAR BIOSCIENCES, INC.Similar federal contract value in Biotech · $4.1M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .